StepStone Group’s Revolution Medicines RVMD Stock Holding History

StepStone Group’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,971	Closed	-$476K	–	22
2025 Q4	$476K	Buy	+5,971	New	+$392K	0.25%	17

Other funds holding RVMD

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

StepStone Group's RVMD Position: Q1 2026 in Review

StepStone Group sold out of Revolution Medicines (RVMD) in Q1 2026, closing a stake of 5,971 shares — an estimated $476K sold.

StepStone Group first reported a position in RVMD in Q4 2025 and held it in 1 quarter. The position peaked at $476K in Q4 2025. 514 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

StepStone Group reported no remaining Revolution Medicines position as of Q1 2026 after selling out during the quarter.
StepStone Group sold 5,971 Revolution Medicines shares in Q1 2026, an estimated $476K.
StepStone Group first reported a position in Revolution Medicines in Q4 2025 and held it in 1 quarter.
StepStone Group's Revolution Medicines position peaked at $476K in Q4 2025.
514 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on StepStone Group's 13F filing for Q1 2026, filed 15 May 2026.